ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

3:45PM-4:00PM: Abstract Number: 2636

Autoantibodies to 14-3-3 eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Advances in Axial Spondyloarthritis (2633–2638)

3:45PM-4:00PM: Abstract Number: 2612

Automated, Artificial Intelligence-supported Sonographic Examination of the Hands for the Detection and Quantification of Arthritis and Osteoarthritis in the Hand and Finger Joints in Outpatient Rheumatology Care

Abstracts: Imaging of Rheumatic Diseases (2609–2614)

3:45PM-4:00PM: Abstract Number: 2618

Effect of Implementing a Dashboard with or without a Best Practice Alert on HLA-B*58:01 Testing Rates among Allopurinol Users at VA Medical Centers

Abstracts: Measures & Measurement of Healthcare Quality (2615–2620)

3:45PM-4:00PM: Abstract Number: 2624

Results of Large Multi-Site Pragmatic Clinical Trial Comparing Corticosteroids or Blinded Lidocaine-only Injections in Treating Osteoarthritis of the Knee

Abstracts: Osteoarthritis – Clinical (2621–2626)

3:45PM-4:00PM: Abstract Number: 2630

The Absence of DORIS Remission Is Associated with Greater Risk of Preterm Birth and Preeclampsia in SLE Pregnancies

Abstracts: Reproductive Issues in Rheumatic Disorders (2627–2632)

3:45PM-4:00PM: Abstract Number: 2606

The Impact of Social Media and Artificial Intelligence on Illness Perception and Treatment Adherence in Patients with Rheumatic Diseases

Abstracts: ARP II: Perception, Prediction, and Prevention (2603–2608)

4:00PM-4:15PM: Abstract Number: 2631

Dapirolizumab Pegol, a Novel CD40L Inhibitor, Showed No Adverse Outcomes in an In Vivo Non-Human Primate Reprotoxicity Study and Displayed Minimal to No Human Placental Transfer in an Ex Vivo Study

Abstracts: Reproductive Issues in Rheumatic Disorders (2627–2632)

4:00PM-4:15PM: Abstract Number: 2625

Early Detection of Knee Osteoarthritis – The Role of a Composite Disease Activity Metric: Data from the Osteoarthritis Initiative

Abstracts: Osteoarthritis – Clinical (2621–2626)

4:00PM-4:15PM: Abstract Number: 2607

ERS-RA as a Tool for Cardiovascular Risk Prediction in Established Rheumatoid Arthritis: An External Validation

Abstracts: ARP II: Perception, Prediction, and Prevention (2603–2608)

4:00PM-4:15PM: Abstract Number: 2613

Ga-FAPI-04 PET/CT reveals increased fibroblast activation in synovial and enthesial tissues of psoriasis patients with arthralgia and predicts the development of psoriatic arthritis

Abstracts: Imaging of Rheumatic Diseases (2609–2614)

4:00PM-4:15PM: Abstract Number: 2637

Initial Phospholipid Transferase Activity Is Predictive of Five-Year Sacroiliac Radiographic Progression in Axial Spondyloarthritis: Findings From the DESIR Cohort

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Advances in Axial Spondyloarthritis (2633–2638)

4:00PM-4:15PM: Abstract Number: 2619

What Works? A Consolidated Framework for Implementation Research-Guided Exploration of Patient Safety in Rheumatology Practices

Abstracts: Measures & Measurement of Healthcare Quality (2615–2620)

4:15PM-4:30PM: Abstract Number: 2638

ASembleNet: A Hybrid AI Model for MRI-Based Classification of Ankylosing Spondylitis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Advances in Axial Spondyloarthritis (2633–2638)

4:15PM-4:30PM: Abstract Number: 2614

Impact of Vagus Nerve-Mediated Neuroimmune Modulation on structural joint damage using Gd-MRI RAMRIS imaging in Biologic-Experienced Patients with Rheumatoid Arthritis

Abstracts: Imaging of Rheumatic Diseases (2609–2614)

4:15PM-4:30PM: Abstract Number: 2626

Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo: Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07)

Abstracts: Osteoarthritis – Clinical (2621–2626)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].